KR102809395B1 - 암을 치료하기 위한 조성물 및 방법 - Google Patents
암을 치료하기 위한 조성물 및 방법 Download PDFInfo
- Publication number
- KR102809395B1 KR102809395B1 KR1020217032873A KR20217032873A KR102809395B1 KR 102809395 B1 KR102809395 B1 KR 102809395B1 KR 1020217032873 A KR1020217032873 A KR 1020217032873A KR 20217032873 A KR20217032873 A KR 20217032873A KR 102809395 B1 KR102809395 B1 KR 102809395B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- compound
- erlotinib
- nmr
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819322P | 2019-03-15 | 2019-03-15 | |
| US62/819,322 | 2019-03-15 | ||
| US201962904241P | 2019-09-23 | 2019-09-23 | |
| US62/904,241 | 2019-09-23 | ||
| PCT/US2020/022743 WO2020190765A2 (en) | 2019-03-15 | 2020-03-13 | Compositions and methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210151820A KR20210151820A (ko) | 2021-12-14 |
| KR102809395B1 true KR102809395B1 (ko) | 2025-05-16 |
Family
ID=72521289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217032873A Active KR102809395B1 (ko) | 2019-03-15 | 2020-03-13 | 암을 치료하기 위한 조성물 및 방법 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11377451B2 (https=) |
| EP (1) | EP3938354A4 (https=) |
| JP (2) | JP7474269B2 (https=) |
| KR (1) | KR102809395B1 (https=) |
| CN (2) | CN115215808B (https=) |
| AU (1) | AU2020241703B2 (https=) |
| BR (1) | BR112021018295A2 (https=) |
| CA (1) | CA3133688A1 (https=) |
| CL (1) | CL2021002409A1 (https=) |
| CO (1) | CO2021013496A2 (https=) |
| CR (1) | CR20210498A (https=) |
| IL (1) | IL286350A (https=) |
| MX (1) | MX2021011272A (https=) |
| PH (1) | PH12021552208A1 (https=) |
| SA (1) | SA521430328B1 (https=) |
| SG (1) | SG11202109662YA (https=) |
| WO (1) | WO2020190765A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111868039A (zh) * | 2017-09-26 | 2020-10-30 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| KR102809395B1 (ko) | 2019-03-15 | 2025-05-16 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 암을 치료하기 위한 조성물 및 방법 |
| US20240058340A1 (en) * | 2020-09-21 | 2024-02-22 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022061299A1 (en) * | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Non-invasive functional companion assays for oncogene targeted therapy for brain cancer |
| WO2022061201A1 (en) * | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022155311A1 (en) * | 2021-01-14 | 2022-07-21 | The Regents Of The University Of California | Methods and systems for analysis of drug target engagement and treatment of cancer |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| US20240165132A1 (en) * | 2021-05-12 | 2024-05-23 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| CN113307799B (zh) * | 2021-05-21 | 2022-07-19 | 大连医科大学 | 一种检测葡萄糖醛酸转移酶1a1荧光探针及其应用 |
| EP4405360A4 (en) * | 2021-09-23 | 2025-08-20 | Erasca Inc | POLYMORPHIC FORMS OF EGFR INHIBITOR |
| WO2023244639A1 (en) * | 2022-06-14 | 2023-12-21 | The Regents Of The University Of California | Methods of predicting cns cancer response to treatment with egfr inhibitors |
| WO2024081447A1 (en) * | 2022-10-14 | 2024-04-18 | The Regents Of The University Of California | Egfr inhibitors for treating lung cancer |
| WO2024102177A1 (en) * | 2022-11-08 | 2024-05-16 | The Regents Of The University Of California | Combination therapies for the treatment of brain cancer |
| WO2025117739A1 (en) * | 2023-11-27 | 2025-06-05 | Erasca, Inc. | Compositions and methods for treating cancer |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022061202A1 (en) | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022061201A1 (en) | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022061299A1 (en) | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Non-invasive functional companion assays for oncogene targeted therapy for brain cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
| KR100397792B1 (ko) * | 2001-06-28 | 2003-09-13 | 한국과학기술연구원 | 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법 |
| CN1854130B (zh) | 2005-04-15 | 2011-04-20 | 中国医学科学院药物研究所 | 喹唑啉衍生物、及其制法和药物组合物与用途 |
| WO2008046242A1 (fr) | 2006-10-16 | 2008-04-24 | Institute Of Mataria Medica, Chinese Academy Of Medical Sciences | Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations |
| WO2011035540A1 (zh) | 2009-09-28 | 2011-03-31 | 齐鲁制药有限公司 | 作为酪氨酸激酶抑制剂的4-（取代苯胺基）喹唑啉衍生物 |
| ITPD20110091A1 (it) | 2011-03-24 | 2012-09-25 | Univ Padova | Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico. |
| NZ732511A (en) * | 2014-12-15 | 2018-11-30 | Univ Michigan Regents | Small molecule inhibitors of egfr and pi3k |
| CA2974442A1 (en) * | 2015-02-03 | 2016-08-11 | Trillium Therapeutics Inc. | Novel fluorinated derivatives as egfr inhibitors useful for treating cancers |
| CN105017163A (zh) | 2015-08-25 | 2015-11-04 | 佛山市赛维斯医药科技有限公司 | 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途 |
| US10473255B2 (en) | 2015-12-29 | 2019-11-12 | Ge-Hitachi Nuclear Energy Americas Llc | Reactor pressure vessel including pipe restraint device, and/or a pipe restraint device |
| AU2017204973A1 (en) | 2016-01-06 | 2018-07-12 | Trillium Therapeutics Inc. | Novel fluorinated quinazoline derivatives as EGFR inhibitors |
| CN106432202B (zh) | 2016-09-22 | 2019-04-02 | 郑州大学第一附属医院 | 喹唑啉类衍生物及其应用 |
| CN111868039A (zh) * | 2017-09-26 | 2020-10-30 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| KR102809395B1 (ko) | 2019-03-15 | 2025-05-16 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 암을 치료하기 위한 조성물 및 방법 |
| EP4405360A4 (en) * | 2021-09-23 | 2025-08-20 | Erasca Inc | POLYMORPHIC FORMS OF EGFR INHIBITOR |
| WO2023244639A1 (en) * | 2022-06-14 | 2023-12-21 | The Regents Of The University Of California | Methods of predicting cns cancer response to treatment with egfr inhibitors |
-
2020
- 2020-03-13 KR KR1020217032873A patent/KR102809395B1/ko active Active
- 2020-03-13 BR BR112021018295A patent/BR112021018295A2/pt unknown
- 2020-03-13 MX MX2021011272A patent/MX2021011272A/es unknown
- 2020-03-13 CN CN202210268803.XA patent/CN115215808B/zh active Active
- 2020-03-13 WO PCT/US2020/022743 patent/WO2020190765A2/en not_active Ceased
- 2020-03-13 EP EP20773177.9A patent/EP3938354A4/en active Pending
- 2020-03-13 SG SG11202109662Y patent/SG11202109662YA/en unknown
- 2020-03-13 AU AU2020241703A patent/AU2020241703B2/en active Active
- 2020-03-13 CA CA3133688A patent/CA3133688A1/en active Pending
- 2020-03-13 JP JP2021555445A patent/JP7474269B2/ja active Active
- 2020-03-13 CN CN202080034742.XA patent/CN113811528A/zh active Pending
- 2020-03-13 CR CR20210498A patent/CR20210498A/es unknown
- 2020-03-13 PH PH1/2021/552208A patent/PH12021552208A1/en unknown
-
2021
- 2021-09-13 IL IL286350A patent/IL286350A/en unknown
- 2021-09-14 US US17/475,144 patent/US11377451B2/en active Active
- 2021-09-15 CL CL2021002409A patent/CL2021002409A1/es unknown
- 2021-09-15 SA SA521430328A patent/SA521430328B1/ar unknown
- 2021-10-11 CO CONC2021/0013496A patent/CO2021013496A2/es unknown
-
2022
- 2022-06-29 US US17/853,573 patent/US20230115366A1/en not_active Abandoned
-
2024
- 2024-04-12 JP JP2024064400A patent/JP7789832B2/ja active Active
- 2024-06-12 US US18/741,322 patent/US20250145634A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022061202A1 (en) | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022061201A1 (en) | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022061299A1 (en) | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Non-invasive functional companion assays for oncogene targeted therapy for brain cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3133688A1 (en) | 2020-09-24 |
| CL2021002409A1 (es) | 2022-06-17 |
| CN115215808A (zh) | 2022-10-21 |
| EP3938354A2 (en) | 2022-01-19 |
| SG11202109662YA (en) | 2021-10-28 |
| AU2020241703A1 (en) | 2021-10-14 |
| US20220064177A1 (en) | 2022-03-03 |
| CO2021013496A2 (es) | 2022-01-17 |
| SA521430328B1 (ar) | 2024-03-28 |
| PH12021552208A1 (en) | 2022-05-30 |
| WO2020190765A3 (en) | 2020-11-26 |
| JP7789832B2 (ja) | 2025-12-22 |
| CN115215808B (zh) | 2025-04-18 |
| JP2024102094A (ja) | 2024-07-30 |
| AU2020241703B2 (en) | 2026-02-05 |
| US11377451B2 (en) | 2022-07-05 |
| IL286350A (en) | 2021-10-31 |
| KR20210151820A (ko) | 2021-12-14 |
| JP2022526266A (ja) | 2022-05-24 |
| WO2020190765A2 (en) | 2020-09-24 |
| CR20210498A (es) | 2022-01-11 |
| US20250145634A1 (en) | 2025-05-08 |
| US20230115366A1 (en) | 2023-04-13 |
| EP3938354A4 (en) | 2022-12-28 |
| JP7474269B2 (ja) | 2024-04-24 |
| CN113811528A (zh) | 2021-12-17 |
| BR112021018295A2 (pt) | 2021-11-23 |
| MX2021011272A (es) | 2021-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102809395B1 (ko) | 암을 치료하기 위한 조성물 및 방법 | |
| JP2023159152A (ja) | がんを治療するための組成物及び方法 | |
| ES2598118T3 (es) | Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de PI3Ks | |
| TW202140485A (zh) | 化合物及其用途 | |
| WO2016168704A1 (en) | Ksr antagonists | |
| US20240058340A1 (en) | Compositions and methods for treating cancer | |
| US20230364091A1 (en) | Compositions and methods for treating cancer | |
| HK40083017A (en) | Compositions and methods for treating cancer | |
| EA044668B1 (ru) | Композиции и способы для лечения рака | |
| HK40062377A (en) | Compositions and methods for treating cancer | |
| HK40037064A (en) | Compositions and methods for treating cancer | |
| O’Sullivan Coyne et al. | Role of HSP90 inhibitors in the treatment of cancer | |
| Akbulut | BO-264: Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate | |
| TW202523325A (zh) | 新穎化合物、包含其的醫藥組成物及使用其治療癌症的方法 | |
| Goerguen et al. | MLN-8237 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20211013 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20250214 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20250514 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20250514 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |